Federal Contractor Profile
Melinta Therapeutics, LLC
$47.5M obligated·5 awards·2 agencies·2 NAICS
Federal Contracts
Showing contracts 1–5 of 5 total. Sorted by action date, most recent first. Excludes $0 modifications.
| Date | Agency | PIID | NAICS | Description | Amount |
|---|---|---|---|---|---|
| Sep 25, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123C00022 | 541714 | ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN | $8.6M |
| Sep 12, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123C00022 | 541714 | ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN | $12.8M |
| Sep 5, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123C00022 | 541714 | ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN | $4.6M |
| May 13, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123C00022 | 541714 | ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN | $1.0M |
| Jul 6, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 75A50123C00022 | 541714 | ADVANCE THE DEVELOPMENT OF TWO ANTIBIOTICS FOR USE IN THE PEDIATRIC POPULATION FOR THE TREATMENT OF SERIOUS BACTERIAL INFECTIONS WHERE MULTIDRUG-RESISTANT ORGANISMS ARE COMMON, AND 2) DEVELOP ANTIBIOTICS FOR USE IN PUBLIC HEALTH AND BIOTHREAT EMERGEN | $20.5M |
Get Alerted Before Melinta Therapeutics, LLC's Next Recompete
Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.
Start Free